ALZHEIMER'S

     expertise

specialized expertise

At CRC, we deliver precise, reliable data for Alzheimer’s research, fast. Our expertise ensures that the data you receive is not only accurate but also actionable—helping you make critical decisions quickly. With a dedicated team of experts, we’re committed to supporting every phase of your research. From trial setup to final analysis, we’re here to ensure your study moves forward smoothly. Trust us to support your mission with the urgency and precision it deserves.

5+

AGITATION ASSOCIATED WITH DEMENTIA PROGRAMS

30+

AAMI TO SEVERE ALZHEIMER’S

PROGRAMS, PHASE I-III

30+

YEAR PARTNERSHIP WITH LEADING KOLs IN ALZHEIMER’S

endpoint expertise including:

BIOMARKER EXPERTISE

Amyloid Beta Peptides (CSF & Serum)

Neurofilament Light Chain

PET Imaging (Amyloid & Tau)

MRI Brain Volumetrics

Inflammatory Biomarkers

Quantitative EEG and ERP

COGNITIVE & FUNCTIONAL

MMSE

ADAS-Cog

CDR

ADCS-CGI

SDB

ADCS-ADL

FAST

QoL-AD

RBAN

NEUROBEHAVIORAL

ASSESSMENT

NPI

CMAI

EAS


RECENT CRC

    RELATED PUBLICATIONS

A man is kissing a woman on the cheek on the beach.

Safety and tolerability of GRF6019 infusions in Severe Alzheimer’s Disease:

A Phase II Double-Blinded Placebo-Controlled Trial

Journal of Alzheimer's Disease, 2021


Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia

Alzheimer's and Dementia, 2020